AQST — Aquestive Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $349.04m
- $352.70m
- $50.58m
- 29
- 27
- 79
- 42
Annual cashflow statement for Aquestive Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -66.2 | -55.8 | -70.5 | -54.4 | -7.87 |
| Depreciation | |||||
| Non-Cash Items | 14.3 | 11.3 | 36.3 | 10.2 | 5.49 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11.1 | -4.41 | -1.73 | 32 | -5.34 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -60.2 | -45.5 | -33 | -9.79 | -6.38 |
| Capital Expenditures | -0.663 | -0.517 | -0.913 | -2.52 | -0.995 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.663 | -0.517 | -0.913 | -2.52 | -0.995 |
| Financing Cash Flow Items | -6.77 | -3.01 | -0.014 | -0.003 | 9.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 49.6 | 28.5 | 30.1 | 11.6 | 3.97 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.3 | -17.5 | -3.78 | -0.751 | -3.4 |